DIO2及UGT1A1基因多态性与左甲状腺素剂量关系的研究进展

中国临床药理学与治疗学 ›› 2015, Vol. 20 ›› Issue (4): 476-480.

• 综述与讲座 • 上一篇

DIO2及UGT1A1基因多态性与左甲状腺素剂量关系的研究进展

徐佼¹, 陈斌¹, 计成²

¹安徽省芜湖市第二人民医院药剂科,芜湖 241000,安徽;
²南京大学医学院附属鼓楼医院药学部,南京 210008,江苏

收稿日期:2014-07-11 修回日期:2015-01-07 发布日期:2015-05-07
通讯作者: 陈斌,男,学士,副主任药师,研究方向:药事管理。Tel: 0553-3909055 E-mail: chenbinw_0553@126.com
作者简介:徐佼,女,硕士,药师,研究方向:药理学。Tel: 0553-3907288 E-mail: wheyxj@163.com

Research progress in association of the DIO2 and UGT1A1 gene polymorphisms with Levothyroxine dose

XU Jiao¹, CHEN Bin¹, JI Cheng²

¹ Department of Pharmacy, the Second People's Hospital of Wuhu, Wuhu 241000, Anhui, China;
² Department of Pharmacy, the Affiliated Drum Tower Hospital of Nanjing University Medical School, Nanjing 210008, Jiangsu, China

Received:2014-07-11 Revised:2015-01-07 Published:2015-05-07

摘要/Abstract

摘要： 甲状腺功能减退症是由于各种原因所致的甲状腺激素合成和分泌减少或组织利用不足,为最常见的内分泌系统疾病之一。左甲状腺素(levothyroxine, L-T₄)是治疗该病的首选药物,但约10%的甲状腺功能减退症患者应用L-T₄替代治疗效果不佳。影响L-T₄治疗达标的因素除了年龄、合并用药、患者的依从性等外,遗传因素是另一重要因素,如Ⅱ型脱碘酶基因(type 2 deiodinase gene, DIO2)和尿苷二磷酸葡萄糖醛酸转移酶(uridine diphosphate glucuronosyltransferase, UGT)1A1基因多态性。了解基因多态性与原发性甲状腺功能减退症患者L-T₄治疗剂量间的关系,可以进一步改善患者的预后,为临床用药提供参考依据。

关键词: 左甲状腺素, 剂量, 基因多态性, DIO2, UGT1A1

Abstract: Hypothyroidism occurs as a result of underproduction or underutilization of thyroid hormone due to various causes. It is one of the most common endocrine disorders. Oral levothyroxine (L-T₄) is the drug of choice for the management of hypothyroidism. But approximately 10% of hypothyroid patients are dissatisfied with the outcome of L-T₄ replacement. Several factors can affect achieving the goals with L-T₄ therapy; in addition to age, concurrent medications, patient compliance and so on, genetic factors are also important, such as the type 2 deiodinase gene (DIO2) and the uridine diphosphate glucuronosyltransferase (UGT) 1A1 gene polymorphisms. To understand the association between gene polymorphisms and L-T₄ dose in patients with primary hypothyroidism will be further improved patient outcomes and provide reference for clinical use.

Key words: levothyroxine, dosing regimen, gene polymorphism, DIO2, UGT1A1

中图分类号:

R968
R977.1

徐佼, 陈斌, 计成. DIO2及UGT1A1基因多态性与左甲状腺素剂量关系的研究进展[J]. 中国临床药理学与治疗学, 2015, 20(4): 476-480.

XU Jiao, CHEN Bin, JI Cheng. Research progress in association of the DIO2 and UGT1A1 gene polymorphisms with Levothyroxine dose[J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2015, 20(4): 476-480.

参考文献

[1] 中华医学会内分泌学分会. 甲状腺疾病诊治指南-甲状腺功能减退症[J]. 中华内科杂志,2007,46(11):967-971.
[2] 初蕾. 甲状腺功能减退患者甲状腺素替代治疗临床分析[J]. 中国临床药理学与治疗学,2013,18(4):420-423.
[3] Garber JR, Cobin RH, Gharib H, et al. Clinical practice guidelines for hypothyroidism in adults: cosponsored by the American Association of Clinical Endocrinologists and the American Thyroid Association[J]. Endocr Pract, 2012, 18(6):988-1028.
[4] Wiersinga WM. Do we need still more trials on T4 and T3 combination therapy in hypothyroidism[J] ? Eur J Endocrinol, 2009, 161(6):955-959.
[5] Williams GR, Bassett JH. Deiodinases: the balance of thyroid hormone: local control of thyroid hormone action: role of type 2 deiodinase[J]. J Endocrinol, 2011, 209(3):261-272.
[6] Arrojo E Drigo R, Fonseca TL, Werneck-de-Castro JP, et al. Role of the type 2 iodothyronine deiodinase (D2) in the control of thyroid hormone signaling[J]. Biochim Biophys Acta, 2013, 1830(7):3956-3964.
[7] Celi FS, Canettieri G, Mentuccia D, et al. Structural organization and chromosomal localization of the human type II deiodinase gene[J]. Eur J Endocrinol, 2000, 143(2):267-271.
[8] Hoftijzer HC, Heemstra KA, Visser TJ, et al. The type 2 deiodinase ORFa-Gly3Asp polymorphism (rs12885300) influences the set point of the hypothalamus-pituitary-thyroid axis in patients treated for differentiated thyroid carcinoma[J]. J Clin Endocrinol Metab, 2011, 96(9):E1527-E1533.
[9] Al-azzam SI, Alkhateeb AM, Al-Azzeh O, et al. The role of type II deiodinase polymorphisms in clinical management of hypothyroid patients treated with levothyroxine[J]. Exp Clin Endocrinol Diabetes, 2013, 121(5):300-305.
[10]Bianco AC, Casula S. Thyroid hormone replacement therapy: three 'simple' questions, complex answers[J]. Eur Thyroid J, 2012, 1(2):88-98.
[11]Cooper DS, Doherty GM, Haugen BR, et al. Revised American Thyroid Association management guidelines for patients with thyroid nodules and differentiated thyroid cancer[J]. Thyroid, 2009, 19(11):1167-1214.
[12]Torlontano M, Durante C, Torrente L, et al. Type 2 deiodinase polymorphism (threonine 92 alanine) predicts L-thyroxine dose to achieve target thyrotropin levels in thyroidectomized patients[J]. J Clin Endocrinol Metab, 2008, 93(3):910-913.
[13]Heemstra KA, Hoftijzer HC, van der Deure WM, et al. Thr92Ala polymorphism in the type 2 deiodinase is not associated with T₄ dose in athyroid patients or patients with Hashimoto thyroiditis[J]. Clin Endocrinol, 2009, 71(2):279-283.
[14]Richardson VM, Ferguson SS, Sey YM, et al. In vitro metabolism of thyroxine by rat and human hepatocytes[J]. Xenobiotica, 2014, 44(5):391-403.
[15]Stingl JC, Bartels H, Viviani R, et al. Relevance of UDP-glucuronosyltransferase polymorphisms for drug dosing: A quantitative systematic review[J]. Pharmacol Ther, 2014, 141(1):92-116.
[16]Kato Y, Ikushiro S, Emi Y, et al. Hepatic UDP-glucuronosyltransferases responsible for glucuronidation of thyroxine in humans[J]. Drug Metab Dispos, 2008, 36(1):51-55.
[17]Sugatani J. Function, genetic polymorphism, and transcriptional regulation of human UDP-glucuronosyltransferase (UGT) 1A1[J]. Drug Metab Pharmacokinet, 2013, 28(2):83-92.
[18]Beutler E, Gelbart T, Demina A. Racial variability in the UDP-glucuronosyltransferase 1 (UGT1A1) promoter: a balanced polymorphism for regulation of bilirubin metabolism[J]? Proc Natl Acad Sci USA, 1998, 95(14):8170-8174.
[19]Yoder Graber AL, Ramírez J, Innocenti F, et al. UGT1A1^*28 genotype affects the in-vitro glucuronidation of thyroxine in human livers[J]. Pharmacogenet Genomics, 2007, 17(8):619-627.
[20]Vargens DD, Neves RR, Bulzico DA, et al. Association of the UGT1A1-53(TA)_n polymorphism with L-thyroxine doses required for thyrotropin suppression in patients with differentiated thyroid cancer[J]. Pharmacogenet Genomics, 2011, 21(6):341-343.
[21]Santoro AB, Vargens DD, Barros Filho Mde C, et al. Effect of UGT1A1, UGT1A3, DIO1 and DIO2 polymorphisms on L-thyroxine doses required for TSH suppression in patients with differentiated thyroid cancer[J]. Br J Clin Pharmacol, 2014, 78(5):1067-1075.
[22]Al-Azzam SI, Alzoubi KH, Khabour O, et al. The associations of polymorphisms of TSH receptor and thyroid hormone receptor genes with L-thyroxine treatment in hypothyroid patients[J]. Hormones (Athens), 2014, 13(3):389-397.

DIO2及UGT1A1基因多态性与左甲状腺素剂量关系的研究进展

Research progress in association of the DIO2 and UGT1A1 gene polymorphisms with Levothyroxine dose

PDF (PC)

可视化

被引次数

摘要/Abstract

引用本文

使用本文

参考文献

相关文章 15

编辑推荐

Metrics

本文评价

[1]	李青华, 赵艳, 赵海港, 高朋飞, 徐炳欣. ABCB1 G2677T 基因多态性检测在缺血性脑卒中患者应用阿托伐他汀降脂治疗中的价值[J]. 中国临床药理学与治疗学, 2023, 28(6): 633-640.
[2]	朱丽, 魏兵, 廖世峨, 张超, 郑晓宇, 刘亚军. 药物代谢酶细胞色素P450单核苷酸多态性影响哮喘儿童吸入皮质醇激素疗效研究[J]. 中国临床药理学与治疗学, 2023, 28(5): 536-543.
[3]	张志英, 靳秀红, 张小宁, 张向峰, 罗青林, 张松林. TBX21和ADCY9多态性在儿童哮喘发生发展中的临床研究[J]. 中国临床药理学与治疗学, 2023, 28(4): 407-412.
[4]	刘璐, 石雨菲, 何庆烽, 徐凤艳, 王鲲, 蔡卫民, 相小强. 群体模型分析方法评估基因多态性对药物PK/PD的影响[J]. 中国临床药理学与治疗学, 2023, 28(11): 1275-1282.
[5]	王爽, 刘嘉, 张月丽. POR*28基因多态性与中国肾移植患者他克莫司稳定剂量的相关性研究[J]. 中国临床药理学与治疗学, 2022, 27(9): 991-997.
[6]	付虹, 田磊. 缺血性脑卒中伴高血压病患者个体化精准治疗的研究[J]. 中国临床药理学与治疗学, 2022, 27(8): 870-876.
[7]	陈文刚, 殷勤, 张巍巍, 周露露, 寇婉青, 袁小龙. 皖南地区高血压患者MTHFR基因多态性分布及与血Hcy相关性研究[J]. 中国临床药理学与治疗学, 2022, 27(7): 768-774.
[8]	武元竹, 刘俊, 杨魁, 彭静, 栾家杰, 韦俊, 张大发, 宋帅, 袁小龙, 王中方, 张年宝, 解丹, 姜鹏, 范洁. 安徽地区汉族人群CYP2C9*3和VKORC1-1639G>A基因多态性分布及对华法林稳定剂量的影响[J]. 中国临床药理学与治疗学, 2022, 27(6): 652-659.
[9]	连金芳, 刘亦伟, 林翠鸿, 黄品芳, 林荣芳. 华法林PPK/PD模型与多元回归法剂量模型的预测准确度比较[J]. 中国临床药理学与治疗学, 2022, 27(3): 267-273.
[10]	王甜甜, 曹俊杰, 刘旭辉, 裴仁治, 陆滢. 氟达拉滨联合后置环磷酰胺用于单倍体造血干细胞移植临床疗效分析[J]. 中国临床药理学与治疗学, 2022, 27(3): 295-301.
[11]	陈佳音, 王丽, 王立军, 童刚领, 马洁, 陈西敬, 卢杨. 有机阳离子转运体基因多态性与奥沙利铂毒性及疗效的相关性研究[J]. 中国临床药理学与治疗学, 2022, 27(2): 171-177.
[12]	温都苏, 王毅, 孙建军. 贝叶斯法与多元线性回归法预测华法林剂量模型的比较研究[J]. 中国临床药理学与治疗学, 2022, 27(1): 33-38.
[13]	邓锟红, 刘亚昕, 孙媛媛, 陈文静, 杨楠, 胡展晴, 陈凯锋, 黄洁, 项玉霞, 阳国平. 2009－2020年药物首次人体试验设计及结果文献分析[J]. 中国临床药理学与治疗学, 2022, 27(1): 77-85.
[14]	周敏敏, 余露, 韩超, 顾达民, 雷道赟. 人类胆固醇酯转移蛋白rs5882基因多态性与围术期神经认知功能紊乱的相关性[J]. 中国临床药理学与治疗学, 2021, 26(7): 768-774.
[15]	王春玲, 周仁精, 冯瑞, 吴燕能. 脂联素45 T/G基因多态性对利拉鲁肽治疗2型糖尿病患者的临床疗效[J]. 中国临床药理学与治疗学, 2021, 26(3): 312-317.